SynAct Pharma partners with Hipolabor to develop, commercialize resomelagon for dengue in Brazil
Bitget2026/10/27 13:58- SynAct Pharma signed a co-development and commercialization agreement with Hipolabor Farmacêutica for resomelagon to treat dengue in Brazil.
- The partners will split profits equally, with additional sales milestone payments linked to cumulative net sales of USD 200 million.
- Development costs for securing Brazilian regulatory approval will be shared equally.
- SynAct retains full control over resomelagon, including rights to pursue partnerships in other indications and territories.
- RESOVIR-2 Part 1 results are expected in 2026 pending regulatory feedback; full-study topline results are expected in the second quarter of 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
